FILOWM4-WaZaBi

Study Design: Open label phase 2 study 

Patients: previously treated for Waldenström macroglobulinemia

Treatment:  zanubrutinib and BGB-11417 combination

Status of the Study: Ongoing, recruiting

Sponsor: FILO French innovative leukemia organization, Kamel Laribi

further informations